Discrimination of sinus rhythm, atrial flutter, and atrial fibrillation using bipolar endocardial signals

Health-Related Quality of Life in Patients Newly Diagnosed with Atrial Fibrillation

INTRODUCTION

Atrial fibrillation is the most common sustained cardiac rhythm disturbance encountered in clinical practice. Despite its high prevalence and the associated high number of hospital admissions, few studies document the actual impact of atrial fibrillation on the patient.

PURPOSE

The purpose of this study was to describe the health-related quality of life (HRQOL) and to examine the impact of seriousness of illness on HRQOL in patients newly diagnosed with atrial fibrillation.

METHODS AND RESULTS

A descriptive correlational and cross-sectional survey study included 81 subjects newly diagnosed with atrial fibrillation within 6 months prior to data collection through face-to-face interview by the Atrial Fibrillation Symptom Frequency and severity checklist (SCL) and the short form-36 health survey (SF-36). As the variables for HRQOL, subjects' perception of both physical health and mental health was poorer than that of general US population. The seriousness of illness had a significant inverse relationship with HRQOL, including both physical health and mental health.

CONCLUSION

The findings of this study indicated that the HRQOL in patients newly diagnosed with atrial fibrillation was significantly impaired and the subjective seriousness of illness had a pivotal impact on HRQOL in atrial fibrillation.

Uncertainty and Its Antecedents in Patients With A trial Fibrillation

The aim of this descriptive, correlational, and cross-sectional survey was to explore uncertainty in patients with atrial fibrillation and to examine the relationships between uncertainty and its antecedents, including education, social support, and perceived seriousness of illness in patients newly diagnosed with atrial fibrillation. The theoretical framework of the study was Mishel’s middle-range nursing theory of uncertainty in illness. A convenience sample of 81 participants recruited from two academic medical centers over 10 months was interviewed. Uncertainty was moderately high in patients with atrial fibrillation compared to other clinical populations. Among antecedents of uncertainty, higher education was significantly associated with less uncertainty (= -.21 to -.25). Except for tangible support, persons with greater social supports perceived less uncertainty (= -.25 to -.27), and individuals with greater perceived seriousness of illness reported greater uncertainty (= .30 to .33).

Satisfaction With Treatment and Prevalence of Discomfort After External Electrical Cardioversion

The objective of this study was to evaluate patient satisfaction with direct current (DC) cardioversion and the prevalence of discomfort after the process. A descriptive study of patients (N = 75) who underwent DC cardioversion in the cardiology department of the Juan Canalejo Hospital, Spain, was conducted. As many as 53.8% of the patients stated that they experienced discomfort with DC cardioversion. The factors associated with relatively more discomfort were being a female and younger age. Receiving information before DC cardioversion protected against discomfort (OR = 0.16). All of the patients were satisfied with the way they were treated, but 21.2% were not satisfied with the results. After adjusting for different covariates, patients who were informed about cardioversion before the procedure were more satisfied with the treatment (OR = 4.9). The patients showed a high degree of satisfaction with the treatment received. Information increases the probability of satisfaction and decreases discomfort.

Predictors and Clinical Impact of Atrial Fibrillation After Pacemaker Implantation in Elderly Patients Treated with Dual Chamber Versus Ventricular Pacing

The Pacemaker Selection in the Elderly (PASE) trial was a prospective, multicenter, single blind, randomized comparison of single chamber, rate adaptive, ventricular pacing (VVIR) with dual chamber, rate adaptive pacing (DDDR) in 407 patients aged > or =65 years(mean 76 +/- 7 years, 60% male)with standard bradycardia indications for dual chamber pacemaker implantation. The incidence, predictors, and clinical consequences of atrial fibrillation (AF) developing after pacemaker implantation in the PASE trial were studied prospectively. During a median follow-up of 18 months, AF developed in 73 (18%) patients. Kaplan-Meier estimated cumulative incidences of AF in patients with sinus node dysfunction (n=176) at 18 months were 28% in the VVIR and 16% in the DDDR groups (P=0.08). After adjustment for other clinical variables using a Cox multivariate regression model, randomization to VVIR compared with DDDR pacing mode among patients with sinus node dysfunction was independently associated with a 2.6-fold increased relative risk (RR) of developing AF after pacemaker implantation (P=0.01). Other independent clinical risk factors for development of postimplant AF included a preimplant history of hypertension (P=0.02) or supraventricular tachyarrhythmias(P<0.04). Patients who developed AF had similar health related quality of life scores and cardiovascular functional status after 18 months of pacing as patients who remained free of AF. The RR of death, stroke, or heart failure hospitalization was not increased in patients who developed AF. Thus, in the elderly patients with sinus node dysfunction requiring permanent pacing, DDDR pacing mode protected against the development of AF. However, development of AF after pacemaker implantation in this population was not associated with a significant impact on quality-of-life, functional status, or other clinical endpoints during 18 months of follow-up.

Evolving concepts in the treatment of atrial fibrillation

Atrial fibrillation (AF) is common among older adults, and its prevalence is increasing due to an aging population. This article reviews the recent insights into the mechanisms of AF, new developments in pharmacologic and nonpharmacologic therapy, and the impact of recent randomized clinical trials in the management of AF. Randomized clinical trials have shown that rhythm control with antiarrhythmic drugs offers no advantage over rate control for the prevention of death and cardiovascular morbidity. Catheter ablation of AF may play an increasingly important role in the future.

Incidence and rate characteristics of atrial tachyarrhythmias in patients with a dual chamber defibrillator

Atrial tachyarrhythmias play an important role in the treatment of patients with malignant ventricular tachyarrhythmias not only with respect to inappropriate discharges but also to left ventricular function and stroke risk. A combined dual chamber defibrillator provides separate therapies for atrial and ventricular tachyarrhythmias. To assess the incidence of atrial tachyarrhythmias in patients with this dual chamber implantable defibrillator, 40 patients with ventricular tachyarrhythmias and concomitant atrial tachyarrhythmias and/or AV conduction disturbances were included in a prospective study. During a mean follow-up of 25 +/- 11 months, 26 of 40 patients had a total of 1,430 recurrences of atrial tachyarrhythmias. The vast majority of the atrial tachyarrhythmias with regular atrial cycles had a mean median atrial cycle length of 235 +/- 37 ms and a mean duration of 34 +/- 144 minutes. Atrial tachyarrhythmias with irregular atrial cycles exhibited a median atrial cycle length of 198 +/- 31 ms and had a mean duration of 246 +/- 1,264 minutes. In addition, 67% of 375 tachyarrhythmias, in which the median ventricular cycle length during the ongoing episode could be documented, had a ventricular rate <100 beats/min. Continuous atrial arrhythmia detection with a dual chamber ICD reveals a high incidence of atrial tachyarrhythmias with a predominantly short duration of paroxysmal recurrences <1 hour in the vast majority of episodes.

Detection of atrial arrhythmia for cardiac rhythm management by implantable devices

Implantable atrial defibrillators (IAD) should provide pacing therapy whenever appropriate (ie, typical atrial flutter) to minimize shock-related patient discomfort. Additionally, IADs should provide diagnostics regarding atrial arrhythmia type and frequency of occurrence to enable improved physician management of atrial arrhythmia. To achieve this, IADs should accurately classify atrial arrhythmia such as atrial fibrillation (AF) and atrial flutter (AFL) This article evaluates the performance of an algorithm, atrial rhythm classification (ARC), designed to classify AF and AFL. The ARC algorithm uses maximum rate, standard deviation, and range of the 12 most recent atrial cycle lengths to plot a point in a three-dimensional space. A decision boundary divides the space into 2 regions--faster/unstable atrial cycle lengths (AF) or slower/stable cycle lengths (AFL). Classifications are made on a sliding window of 12 consecutive cycles until the end of the episode is reached. In this way, continuous episode feedback is provided that can be used to help guide device therapy, measure arrhythmia type and frequency of occurrence. Bipolar (1-cm) electrogram episodes of AF (n = 16) and AFL (n = 7) were acquired from 20 patients and retrospectively analyzed using the ARC algorithm. The sensitivity and specificity in this study was 0.993 and 0.982, respectively. The ARC algorithm would have appropriately guided atrial therapy and minimized discomfort associated with defibrillation shocks in this small patient data set warranting further studies. The ARC algorithm may also be beneficial as a diagnostic tool to assist physician management of atrial arrhythmia.

Implantable dual-chamber cardioverter-defibrillator-pacemaker

The fifth generation of implantable cardioverter-defibrillators offer enhanced modes of detection of atrial and ventricular arrhythmias, antitachycardia pacing and shocks, multiprogrammability, intracardiac electrogram storage, and all functions of antibradycardia dual-chamber pacing including rate responsiveness and mode switching. There is no consensus on the indications for dual-chamber pacemaker defibrillator systems. This review focuses on the four major options of newer devices that might benefit patients: 1) permanent dual-chamber pacing in ischemic coronary disease patients, 2) detection and management of atrial fibrillation or other atrial tachyarrhythmias, 3) some newer indications for pacing, and 4) the suppression of inappropriate interventions. On the basis of published data, newer indications for the dual-chamber systems, advantages and limitations, and future perspectives are discussed.

Effects of the maze operation on health-related quality of life in patients with atrial fibrillation

BACKGROUND

Maze surgery for atrial fibrillation (AF) is a curative therapy, but its effect on health-related quality of life has not been studied.

METHODS AND RESULTS

Maze operations were performed in 48 patients with drug-refractory AF. The majority of patients (80%) had lone AF, and the primary indication for surgery in all patients was AF. The SF-36 Health Survey was used to assess quality of life before operation and at 6 months and 1 year after surgery. Twenty-five patients were available for the 1-year follow-up and completed all questionnaires. Before maze surgery, the SF-36 scores were significantly lower than in the general Swedish population, reflecting significant impairment in well-being, physical and social functioning, and mental health. After maze surgery, the quality of life was significantly improved at 6 months and at 1 year on all scales except for bodily pain, which, however, was not significantly decreased before surgery. At both 6 months and 1 year after maze surgery, quality of life, measured by the SF-36, reached the levels of the general Swedish population.

CONCLUSIONS

The maze operation can significantly improve the health-related quality of life in selected groups of patients with both paroxysmal and chronic AF refractory to antiarrhythmic therapy.

Automated classification of human atrial fibrillation from intraatrial electrograms

The assessment of the degree of organization and the classification of atrial fibrillation (AF) according to the types defined by Wells usually resorts to the visual inspection of bipolar intraatrial electrograms. The focus of this study was to test seven parameters aimed to quantify the degree of organization of the electrograms, and then to design a final classification scheme based on a multidimensional, minimum-distance analysis. The following parameters were tested: mean atrial period (AP) and its coefficient of variation (CV); number of points lying at the baseline (NO) and the Shannon entropy (EN) of the amplitude probability density function (APDF); depolarization width (F-WIDTH); and correlation waveform analysis (CWA) and electrogram bandwidth (BW). The signal database consisted in a set of 160 AF strips of Type I, II, and III AF, scored by an expert cardiologist (60 Type I, 40 Type II, 60 Type III) and further divided in a training set (60) and a test set (100). Strips were 6 seconds long and were recorded with 5-mm interspace bipolar catheters from electrically induced (n = 13) and chronic (n = 10) patients. A classification algorithm based on a minimum-distance (Mahalanobis distance) discriminant analysis was tested. Using a single parameter, the best discriminations were provided by NO, F-WIDTH, and CV. F-WIDTH was found strongly inversely correlated to NO (r = -0.90). Of all the two-parameter combinations, CV-NO provided the best classification: 92 of 100 segments were correctly classified with sensitivity > 90% and specificity > 92%. A further improvement was obtained by including BW as a third parameter (93/100 correctly classified). The use of more than three parameters not only failed to improve, but even degraded the classification.

Clinical experience with the new detection algorithms for atrial fibrillation of a defibrillator with dual chamber sensing and pacing

INTRODUCTION

A major drawback of therapy with an implantable defibrillator is the nonspecificity of detection. Theoretically, adding atrial sensing information to a decision algorithm could improve specificity of detection.

METHODS AND RESULTS

This open-label nonrandomized study compares the detection algorithm of the Ventak AV and the Ventak Mini implantable defibrillators. The Ventak AV (n = 39) uses dual chamber detection as opposed to single chamber detection (with rate stability) in the Ventak Mini (n = 55). Programmed zone configurations, rate thresholds, and stability criteria were identical in all patients. In the Ventak AV group, 235 ventricular tachyarrhythmias were adequately detected and treated by the device. In the Mini group, 699 episodes of ventricular fibrillation/tachycardia occurred. All but six of the latter episodes were correctly identified and treated: one patient with incessant ventricular tachycardia had five episodes not terminated by the device, another episode occurred in a patient with a device/lead defect. In the Ventak AV group, 33 episodes of sinus tachycardia and 166 episodes of atrial fibrillation/flutter activated the device; inappropriate therapy was applied to 41% of atrial fibrillation/flutter episodes. In the Ventak Mini group, 226 supraventricular tachyarrhythmias activated the device, eight of which were sinus tachycardia and 218 were atrial fibrillation or flutter; of the atrial fibrillation/ flutter episodes 24% were treated inappropriately (fewer vs Ventak AV, P < 0.001).

CONCLUSION

The new detection algorithm incorporated in the Ventak AV did not inadvertently withhold therapy for ventricular tachyarrhythmias, but at the same time the number of inappropriate therapies for atrial fibrillation was not decreased in comparison to a single chamber device.

How smart should pacemakers Be?

The concept of the "smart" pacemaker has been continuously changing during 40 years of progress in technology. When we talk today about smart pacemakers, it means optimal treatment, diagnosis, and follow-up for patients fitting the current indications for pacemakers. So what is smart today becomes accepted as "state of the art" tomorrow. Originally, implantable pacemakers were developed to save lives from prolonged episodes of bradycardia and/or complete heart block. Now, in addition, they improve quality of life via numerous different functions acting under specific conditions, thanks to the introduction of microprocessors. The devices have become smaller, with the miniaturization of the electrical components, without compromising longevity. Nevertheless, there are still some unmatched objectives for these devices, for example, the optimization of cardiac output and the management of atrial arrhythmias in dual-chamber devices. Furthermore, indications continue to evolve, which in turn require new, additional functions. These functions are often very complex, necessitating computerized programming to simplify application. In addition, the follow-up of these devices is time-consuming, as appropriate system performance has to be regularly monitored. A great many of these functions could be automatically performed and documented, thus enabling physicians and paramedical staff to avoid losing time with routine control procedures. In addition, modern pacemakers offer extensive diagnostic functions to help diagnose patient symptoms and pacemaker system problems. Different types of data are available, and their presentation differs from one company to the other. This huge amount of data can only be managed with automatic diagnostic functions. Thus, the smart pacemaker of the near future should offer high flexibility to permit easy programming of available therapies and follow-up, and extensive, easily comprehensible diagnostic functions.

Technologic advances in implantable cardioverter defibrillators

Multiple technologic advances in the implantable cardioverter defibrillator (ICD) have resulted in smaller size, easier implantation, and improved detection, therapy, and stored diagnostic information. Advanced dual-chamber ICDs are currently available that allow dual-chamber rate-responsive pacing with mode switching, enhanced detection algorithms, antitachycardia pacing, low-energy cardioversion, high-energy shocks, and extensive diagnostics. Based on improvements in lead systems and improved energy waveforms, almost all devices are being implanted with nonthoracotomy leads in the pectoralis area. The results of recent clinical trials have expanded indications for the ICD for primary and secondary prevention of sudden cardiac death. With advances in capacitor and battery technology coupled with improved lead systems and waveform resulting in lower defibrillation thresholds, it is likely that lower-output, smaller devices will be developed. In the future, ICDs may have expanded indications and may incorporate physiologic sensors to access hemodynamic significance of arrhythmias and algorithms for prediction and prevention of cardiac arrhythmias.